 |
Genentech DNA (news,
chart,
quote) - DNA calls active on Endpoint miss
DNA is recently down $4.87 to $69.30. DNA and BIIB announced that the phase three EXPLORER study, evaluating Rituzan in Systemic Lupus Erythematosus (SLE) failed to meet its primary endpoin |
|
